Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label multidose study of ARC-AAT in alpha-1 antitrypsin deficiency-related liver disease
2016-000917-59Phase 2Terminated
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Apr 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alpha-1-proteinase inhibitor in alpha-1 antitrypsin deficiency (AATD), sponsored by Arrowhead Pharmaceuticals. Primary endpoint: Safety and tolerability of repeated doses of ARC-AAT Injection. Started Apr 2016; status: terminated.
02
Drugs
alpha-1-proteinase inhibitor
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on 2016-000917-59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000917-59.